Over 30 years ago, receptors for the Fc region of IgG (FcgR) were implicated in the pathogenesis of systemic lupus erythematosus (SLE). Since those pioneering studies, our knowledge of the structure and function of these FcgRs has increased dramatically. We now know that FcgR contributes to the regulation of acquired immunity and to the regulation of innate immune responses where FcgRs act as specific receptors for innate opsonins (CRP and SAP). Our understanding of the genomic architecture of the genes encoding the FcgR has also witnessed remarkable advances. Numerous functionally relevant single-nucleotide polymorphism (SNP) variants and copy number (CN) variants have been characterized in the FcgR genes. Many of these variants have also been shown to associate with risk to development of SLE and some have been associated with disease progression. This review will provide an overview of the FcgR in relation to SLE, including consideration of the role of genetic variants in FcgR in SLE pathogenesis. The difficulties in assessing genetic variation in these genes will be discussed. To enhance our understanding of the functional roles of these receptors in SLE, future research will need to integrate our knowledge of SNP variants, CN variants and the functional diversity of these receptors.
Introduction
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by the presence of autoreactive B cells and the formation and deposition of antibody-antigen immune complexes (IC) consistent with the diathesis, which involves multiple organ systems. Evidences from familial aggregation studies, [1] [2] [3] [4] [5] together with a high concordance among monozygotic twins, [6] [7] [8] suggest a genetic contribution. However, a single gene with a clearly causal Mendelian effect has not been identified, underscoring a multigenic mode of inheritance. Among the quantitative trait loci identified from candidate gene-association studies of murine lupus models and diverse human populations, consistent linkage at chromosome 1q21.1-24, a region that includes a functionally and structurally diverse group of receptors that recognize the constant (Fc) portion of specific immunoglobulin (Ig) isotypes, has been shown [9] [10] [11] [12] [13] [14] [15] . Consistent with a role for receptors for the Fc region of IgG (FcgR), the pathogenesis of SLE involves the production of autoantibodies, resulting in IC formation. Altered or delayed clearance of these autoantibodycontaining ICs results in the deposition of these ICs in various tissues, eliciting inflammation and damage by engaging FcgRs and complement. Even from decades ago it was well known that FcgR expression levels and function were altered in SLE. The classic antibody opsonized erythrocyte (EA) clearance studies 16, 17 showed delayed in vivo FcgR-mediated clearance in patients with SLE and ex vivo studies showed altered FcgR functions such as phagocytosis. 18 These alterations in FcgR function correlate with disease activity, suggesting that disease activity may alter receptor function. However, extensive studies of FcgRs in both animal models and human population studies have since been performed, 19, 20 and several functional genetic polymorphisms have been identified and associated with SLE in several ethnic populations. Thus, FcgR function in patients with SLE is influenced by both inherited genetic variation and by acquired differences in function attributable to disease activity.
Fc receptors are a heterogeneous group of hematopoietic cell surface glycoproteins that facilitate the efficiency of antibody-antigen interactions with effector cells of the immune system. These receptors regulate a variety of humoral and cellular immune responses, including phagocytosis, degranulation, antibody-dependent cellular cytotoxicity, transcriptional regulation of cytokine and chemokine expression, B-cell activation and IC clearance. The cellular distribution and Ig isotype (IgA, IgD, IgE, IgG and IgM) specificity influence the regulatory roles of Fc receptors. In addition, common variation in the genes that encode Fc receptors, capable of altering the efficiency of the mononuclear phagocyte system to clear Ig ICs, provides a mechanism for the heritable differences observed in the susceptibility to SLE and subsequent IC-mediated tissue injury. 21, 22 The Fc receptor complex is noteworthy for its high degree of sequence homology, pattern of linkage disequilibrium and common copy number variation (CNV). This group of structurally and functionally diverse receptor genes are co-localized to a region on chromosome 1q21.1-24 that includes the classical Fc receptors for IgG (Fcg) and non-classical Fc-like receptors (FCR1-FCRL6L), Fc receptors for IgE (FceRI) and IgA/IgM (Fca/mR). The consistency of genotype-phenotype findings coupled with the topology of the Fcg receptor gene cluster underscores the importance of this locus as containing susceptibility alleles with potentially deleterious functional consequences.
Human Fcc receptor structure and function
FcgRs bind to the Fc portion of IgG and serve as a crucial link between humoral and cell-mediated immune responses. In addition, more recent data showed that FcgRs also function as receptors for innate immune opsonins (CRP and SAP) and provide a link between innate and acquired immunity. In human, the classical FcgR family is divided into three receptor families (FcgRI (CD64), FcgRII (CD32) and FcgRIII (CD16)) based on structural homology, difference in affinity and differences in specificity for IgG subclasses. These FcgRs are also defined as either activating receptors (FcgRI, FcgRIIA/C and FcgRIII) or as inhibitory receptor (FcgRIIB) as they elicit or inhibit immune functions such as phagocytosis, cytotoxicity, degranulation, antigen presentation and cytokine production through immune tyrosine activating or inhibitory motifs (immunoreceptor tyrosine activation motif (ITAM) or immunoreceptor tyrosine inhibitory motif (ITIM)). These signaling motifs are either on the same ligand-binding a-chain as for FcgRII or on the associated homodimer accessory chains such as the common Fc receptor g-chain (for FcgRI and FcgRIII, Figure 1 ) that is also shared with FceRI and FcaRI. 19 On natural killer (NK) cells, FcgRIIIa associates with a homodimer of the T-cell receptor z-chain. The ligandbinding a-chain of most FcgRs consists of two or three Ig-like domains in the extracellular region, a transmembrane domain and an intracellular cytoplasmic domain.
FcgRI Located in chromosome 1q21, FcgRI is the only highaffinity Fcg receptor that can strongly bind monomeric IgG. This receptor is also unique from other FcgRs in having three extracellular Ig-like domains (see Figure 1) . The FcgRI family has three genes (FCGRIA, FCGRIB and FCGRIC) but only the FcgRIa product of FCGRIA has been identified as a full-length cell surface receptor. 23 FcgRI has been found on the surface of monocytes, dendritic cells (DCs), macrophages and also activated neutrophils. 24 Stable expression of FcgRIa requires the presence of the common FcR g-chain homodimer, resulting in the expression of a complex of FcgRIa (the a-chain)/g-g on the cell surface. FcgRIa can be expressed in the absence of this g-chain homodimer, but its expression is transient.
FcgRII
The FcgRII subclass of receptors on human chromosome 1q23 is composed of three genes (FCGR2A, FCGR2B and FCGR2C) that encode the FcgRIIa, FcgRIIb and FcgRIIc proteins. Expressed on monocytes, certain DCs, neutrophils, B cells, platelets and NK cells, FcgRII (CD32) is the most widely distributed FcgR, with low binding affinity for IgG. 25 With two extracellular Ig-like domains, FcgRII has a low binding affinity for monomeric IgG, but binds IgG aggregates and ICs readily. As mentioned earlier, unlike other FcgRs, the FcgRII proteins bear signaling motifs directly in their intracellular cytoplasmic domains and do not require the common FcR g-chain for stable expression or function. Although the FcgRIIa and FcgRIIc proteins contain the ITAM, the FcgRIIb protein is the only inhibitory Fcg receptor containing an ITIM in its cytoplasmic domain. An additional level of complexity in the FCGR2B locus is that three alternatively spliced transcripts can be expressed: b1 and b2 differ by an insert of 19 amino acids in the FcgRIIb cytoplasmic domain, whereas the b3 form lacks part of the signal sequence. FcgRIIb1 is expressed on B cells as the only currently recognized Fcg receptor on B cells, whereas FcgRIIb2 is found on myeloid cells together with FcgRIIa. The FCGR2C gene has a stop codon (STP)/glutamine (Q) polymorphism at amino-acid position 13 in the first extracellular domain and has been described as an expressed protein on NK cells only when the 13Q allele is present. 26, 27 The FCGR2C gene encodes an extracellular domain that is highly homologous to FcgRIIB and an intracellular cytoplasmic domain that is nearly identical to the cytoplasmic domain of FCGR2A. Characterization of the FCGR2C locus has suggested that the FCGR2C gene is the result of an unequal crossover event between FCGR2A and FCGR2B. 19 On these cells, g-chain (or the T-cell receptor z-chain on NK cells) is necessary for both stable expression of the protein on the cell surface and for signal transduction through the FcgRIIIa receptor complex. Interestingly, in mast cells, the FcgRIIIa receptor complex can also incorporate the b-chain from the IgE receptor, resulting in an a/b/g-g complex on the cell surface.
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The FcgRIIIB gene is unique among the FcgR genes in that it encodes a glycosylphosphatidylinositol-anchored (GPI) receptor, FcgRIIIb. This receptor is expressed on the surface of neutrophils and basophils. 28 It is worth noting that on the surface of neutrophils, FcgRIIIb is highly expressed, with 150 000-200 000 receptors expressed per cell. Biochemical studies have suggested that when FcgRIIIb is expressed on the surface of neutrophils, it interacts with the b2-integrin, CD11b/CD18. This is of interest given the recent demonstration of the strong genetic association between a variant in the CD11b/ ITGAM locus and SLE.
As mentioned above, each FcgR protein has differential ligand-binding preferences with respect to IgG subclasses and differing affinities for IgG subclasses. These preferences are summarized in Table 1 and have been recently reviewed in great detail. 29 It is worth noting that the binding of IgG2 is generally limited to the R131 allele of FcgRIIa, whereas the binding of IgG4 is limited to the 159V allele of FcgRIIIa (see below).
FcgR function
Regulation of cell signaling. Upon cross-linking by IC, activating FcgRs (FcgR associated with the common FcR g-chain or the T-cell receptor z-chain or FcgRIIa/c) initiate a signaling cascade through the ITAM, which normally starts with sequential activation of protein tyrosine kinases of the Src family followed by activation of the Syk tyrosine kinase. 30, 31 This results in the tyrosine phosphorylation of the ITAM itself, with recruitment of various downstream targets, including other kinases, adaptor molecules and other signaling intermediates (see Bezman and Koretzky 32 for a review). In many cell types, activation of phosphoinositide-3 kinase results in the recruitment of phospholipase Cg, which in turn induces a phospholipase Cg-mediated calcium influx triggering different effector functions. 33, 34 In antigen-presenting cells, such as macrophages and DCs, activating FcgRs mediate cell functions such as phagocytosis, respiratory burst and cytokine production (tumor necrosis factor-a and interleukin-6); in neutrophils and NK cells, they trigger antibody-dependent cellular cytotoxicity and degranulation; and in mast cells, they induce degranulation. 35, 36 It is a noteworthy finding that these so-called activating receptors are not merely overlapping in functional properties but in fact have specialized functions that are due in part to the differences in the cytoplasmic domains of the ligand-binding a-chains. For example, a recent study has shown the unique ability of FcgRIa to facilitate antigen presentation. 37 Even more surprising is our recent finding that FcgRIa is unique among FcgR, and among other g-chain-associated Fc receptors, in its ability to regulate the cell surface expression of TNFSF13b (also called BLyS or BAFF) upon cross-linking with either IgG ligand or with the innate immune opsonin, CRP. 38 Other differences in receptor function are the result of differences in cell surface expression. FcgRIIa is unique in its expression on platelets, and cross-linking of FcgRIIa can directly activate platelets resulting in platelet aggregation. Although all of these functions are dependent on the ITAM, it is likely that the sequences in the associated a-chains are also contributing to net receptor function. Indeed, we have shown that the cytoplasmic domain of FcRIa, devoid of any known signaling motifs, modifies g-chain-based signaling and other recent studies have shown that these cytoplasmic domains can recruit different molecules to the receptor complex. Future work will be required to fully delineate the signaling elements engaged by the ITAM-expressing FcgR, and this work promises to provide additional insights into the functions of each of these different FcgRs.
A key function of these activating FcgRs is the removal or clearance of ICs. As noted above, this function is known to be altered in patients with SLE. Of all FcgRs, FcgRIIIa is thought to play an important role in IC clearance. The intermediate affinity of this receptor on macrophages (fixed tissue macrophages) makes it ideally suited as a capture receptor to facilitate clearance. Of 39 A key role for FcgRIIb in regulating autoimmunity has been shown in both murine models and in patients with SLE. Certain mouse strains that are deficient in FcgRIIb develop a spontaneous lupus-like disease, resulting in glomerulonephritis and premature mortality. 40 Conversely, increases in FcgRIIb expression in these mice can restore tolerance and ameliorate the spontaneous autoimmune phenotype. 41 In patients with SLE, alterations in FcgRIIb expression have also been noted. However, disease is associated with increased expression of the FcgRIIb protein on the surface of B cells. Clearly, additional work is needed to more fully understand the critical role of this receptor in the regulation of immune tolerance and autoimmunity.
More recent data from a number of different receptor systems have challenged the conventional ITAM/ITIM concept. 42, 43 Extensive cross-talk, or co-modulation, between receptor systems has now been described and is likely to be pervasive across many different receptor systems. For example, the IgA Fc receptor, FcaRI, can not only activate cells but also cross-inhibit other receptors, including the classical FcgR. Similarly, engagement of receptors containing ITIMs can result in the induction of functional responses such as antigen presentation through FcgRIIb on DCs. The regulation and determination of the activating and inhibitory potential of FcgR are likely influenced through the complex interplay of the degree of receptor cross-linking, the nature of interaction between receptor subunits and the interactions with other cell surface receptors (such as CD11b/CD18).
FccR polymorphisms and association with SLE
Sequencing of the genes in the Fcg receptor cluster has resulted in the identification of numerous genetic variants, including functionally relevant variants. The importance of FcgR variants as SLE susceptibility factors and as factors influencing disease outcomes is highlighted by the consistent association of many of these genetic variants with disease. Table 2 highlights some of the consistent associations observed between FcgR variants and SLE. However, limiting the ability to examine the role of genetic variants in these genes is the high degree of sequence homology between genes ( Figure 2) . Indeed, this sequence homology precludes the assessment of most single-nucleotide polymorphisms FccR and SLE X Li et al (SNPs) in these genes on the currently available genomewide SNP arrays. In the first two published genomewide association studies (GWAS), 44 ,45 the arrays contained only 11 and 19 SNPs across the entire low-affinity FcgR cluster, precluding a detailed analysis of association between these genes and SLE. We will summarize the current knowledge regarding associations between genetic variants in each of the low-affinity classical FcgR and SLE.
FCGR2A
A non-synonymous G-to-A variant in the FCGR2A gene (rs1801274) results in a single amino-acid difference at position 131 (R131 and H131) in the second extracellular Ig-like domain of the FcgRIIa protein. This allelic difference alters recognition of ligand. The FcgRIIA-H131 (histidine residue at position 131) allele is able to bind IgG2 effectively, whereas the R131 (arginine residue at position 131) allele does not bind IgG2. 21, 46 This affinity variation leads to functional difference: phagocytes from homozygous H131 individuals are much more effective than those from homozygous R131 donors in terms of phagocytosis of IgG2-opsonized particles. 47 Several independent studies in multiple ethnic groups have reported the association of R131 with the susceptibility to SLE and/or lupus nephritis in Dutch Caucasians, European-Americans, African-Americans and Koreans, [48] [49] [50] whereas other studies have presented inconsistent results. [51] [52] [53] [54] [55] Karassa et al. 56 did a metaanalysis of 17 published studies and inferred that the R131 allele had 1.3-fold higher risk for SLE susceptibility compared with the H131 allele. Besides contributing to susceptibility, the FcgRIIa-R131 allele was also shown to be related to SLE severity. 57 Haseley et al. 57 found that the presence of 131R/R was associated with renal involvement in patients with IgG2 anti-C1q autoantibodypositive nephritis. Inconsistencies between studies might be attributable to ethnic differences, disease heterogeneity (that is, subclass of autoantibodies) or to genotyping error.
FCGR2B
A non-synonymous T/C SNP in the FCGR2B gene has been identified that results in the change of an isoleucine (I) to threonine (T) substitution at position 187 in the transmembrane domain of the FcgRIIb protein. 58, 59 This single amino-acid substitution has been shown to affect the inhibitory function of FcgRIIb on B cells. The 187T allele is excluded from lipid rafts and has a decreased inhibitory potential toward BCR signaling. 60, 61 Likewise, the 187T allele has been reported to be associated with SLE in Asian populations, including Japanese, Chinese and Thais, 59, 62, 63 but no association has been found in African-American or Caucasian in the United States or Europe. 58, 64 A meta-analysis of association of this variant in FCGR2B with SLE in three independent studies of Asian populations showed an odds ratio of 2.45 for 187T/T vs 187I/I for SLE susceptibility. 60 In 2004, Su et al. 65 identified a promoter haplotype that alters FcgRIIb promoter activity. The less frequent promoter haplotype (À386C-120A) showed increased promoter activity and drove higher receptor expression in both transfected cell lines and on cells ex vivo from genotyped donors than the more frequent haplotype (À386G-120T) . 65, 66 The less frequent and more active promoter haplotype was associated with SLE in a Caucasian population with an odds ratio of 1.6.
65
Confirmation of this association has been published and has shown that the same À386G/C SNP associates with SLE susceptibility. 67 The analysis of these promoter variants in FCGR2B is hampered by complete sequence identity with the proximal promoter of FCGR2C.
Studies examining these SNPs need to take care to ensure gene specificity in any analysis of this genomic region.
FCGR3A
As noted above, FcgRIIIa is thought to play a critical role in IC clearance. In addition, this receptor is an important mediator of antibody-dependent cell-mediated cytotoxicity functions on NK cells. 68 A non-synonymous SNP (rs396991) that encodes a T-to-G change at nt559 results in a phenylalanine (F) to valine (V) amino-acid change at position 159 in the second extracellular domain of the FcgRIIIa protein. These alleles of FcgRIIIA have differing binding affinities for IgG. The FcgRIIIA-158V allele (also known as 176V/F when the leader sequence is included) binds IgG1, IgG3 and IgG4 with higher affinity relative to the 158F (176F) allele. In addition, the increased binding capacity of the 158V allele results in more robust downstream functional effects. Using peripheral blood NK cells from genotyped donors, individuals homozygous for the 159V allele show higher calcium transients, higher induction of CD25 expression and more rapid apoptosis when compared with donors homozygous for 159F. 69, 70 Consistent with a critical role for FcgRIIIa in IC clearance, the lower IgG-binding allele, 158F, is associated with SLE susceptibility in several case-control studies in multiple ethnic groups (Caucasian and African-American).
A role for FcgRIIIa in disease severity has also been shown. Within patients with renal disease, the higher binding 159V allele is associated with development of end-stage renal disease. 71 This result, in conjunction with the SLE susceptibility studies of FCGR3A, shows that this gene can influence not only disease susceptibility but also disease progression. In patients with renal disease, progression to end-stage renal disease is associated with the higher binding allele of FcgRIIIa, consistent with a role for this receptor in promoting more vigorous local inflammatory responses in the kidney.
FCGR3B
Three different allotypic variants of FcgRIIIb, NA1, NA2 and SH, have been identified through serological studies. The sequence bases for these FCGR3B variants are now known (Figure 3) . The six SNP differences underlying these three serologic allotypes include five non-synonymous SNPs and one synonymous SNP. The five aminoacid changes are all in the first extracellular domain of FcgRIIIb (marked as black in Figure 3) , with the aminoacid 65 change resulting in a loss of a glycosylation site in the NA2 allele. 22, 72 The enhanced functional capacity of the NA1 allele is firmly established. Some studies have suggested differing binding affinities for IgG1 and IgG3 between the FcgRIIIB-NA1 and FcgRIIIb-NA2 alleles, with the NA1 allele showing higher binding. Alternatively, the NA1 and NA2 alleles may interact differently with other cell surface receptors, such as the b2-integrin, CD11b/CD18. Interactions with other cell surface recep-tors may be critical or essential to FcgRIIIb function. As noted above, this receptor lacks a transmembrane and cytoplasmic domain and is anchored to the cell surface through a GPI linkage. In the absence of these domains, such inter-molecular interactions may be necessary for FcgRIIIb to function, and glycosylation change between the NA1 and NA2 alleles may alter such interactions.
In a Japanese population, the NA2 allele has been reported as a susceptibility factor for SLE. 73 However, this observation has not been replicated. More recently, a re-examination of the importance of variation-CNV-at the FCGR3B locus has suggested a role for decreased CN of FCGR3B in SLE susceptibility (see below).
Genome-wide association studies
A number of GWAS studies in SLE have now been reported. As noted above, SNP coverage in the lowaffinity Fcg receptor is poor, with some genes (FCGR2C and FCGR3B) receiving no coverage. Nonetheless, a statistically significant association at the non-synonymous H131/R131 variant (rs1801274) was noted in the recent GWAS performed by the International Consortium on Systemic Lupus Erythematosus. 45 The SNPs in other FCGR genes previously associated with SLE were not represented on any of the arrays used in the recent GWAS studies. The presence of high sequence homology between the FCGR genes, with the presence of a segmental duplication in this region (Figure 2 ), precludes any GWAS-based conclusions regarding association at the FCGR3A or FGR2B loci with SLE. In addition, association between SNP variants and SLE in this genomic region may also be confounded by the presence of known CNVs.
CNV in the Fcc receptor cluster
FCGR3B CNV and SLE CNV of FCGR3B in SLE has been known since the 1990s, although it was not reported as such. 74 Although FCGR3B is almost identical at the sequence level to FCGR3A, unique alleles in the 3 0 -most exon have been used to detect FCGR3B CNV. Deficiency (that is, a CN of zero) of FCGR3B was first observed as a lack of all three alleles in two healthy individuals in 1990. 75, 76 An increased CN was later observed through the presence of all three alleles in three individuals. 77 Association of FCGR3B CNV with SLE has been determined using a real-time PCR assay developed by Aitman et al. 78 Relative CN of o2 at the FCGR3B locus was associated with risk for SLE (with and without nephritis). Relative CN of 42 FCGR3B was not significantly associated with protection against SLE but was significantly associated with protection against Addison's disease and Wegener's granulomatosis in a French population. 79 The same assay has been used to show an association of FCGR3B CN with risk for glomerulonephritis and lupus nephritis: increased CN was protective and decreased CN was a risk factor. 78 There is evidence that CNV of FCGR3B is associated with alterations of surface expression on neutrophils, neutrophil adhesion and IC uptake by neutrophils. 80 Deficiencies in these neutrophil functions could cause or contribute to the characteristic buildup of ICs seen in SLE.
CNV of the other FCGR genes in the 1q23 cluster CNV has been reported for other FCGR genes, but no association with SLE has been reported yet. CNVs of FCGR2C and FCGR3B have been reported to be linked. 81 CNV of FCGR2C, assessed by multiplex ligation-dependent probe amplification, was determined to be associated with idiopathic thrombocytopenic purpura. 27 In the same report, CNV of FCGR3A was also reported. CNV of the two remaining receptors in the chromosome 1q23 FCGR cluster, FCGR2A and FCGR2B, has yet to be reported. Although CNV of the other FCGR genes has yet to be associated with SLE, if reported at all, the clear significance of FCGR3B CNV in SLE, the evidence of more extensive CNV in the cluster, and the logical connection between FCGRs and the pathology of SLE suggest that further study of CNV in the 1q23 FCGR cluster is warranted.
Future directions
Efforts to characterize the joint contribution of Fc receptor loci with additional genotypic and environ- FccR and SLE X Li et al mental factors will expedite our understanding of SLE pathogenesis and importantly, its natural history. 
Gene-by-gene interactions
In addition to the Fcg receptors, strong and consistent gene associations were shown across diverse populations for human leukocyte antigens, 70, 72, 82, 83 components of the classical complement activation system belonging to the major histocompatibility complex class III region 70, 72, 83, 84 and more recently, the type I interferon regulatory factor-5 (IRF5), 69, [85] [86] [87] the protein tyrosine phosphatase, PTPN22, 69, 75, 78, [88] [89] [90] ITGAM, PXK and KIAA1542. 45 Despite strong associations with SLE, these susceptibility loci do not sufficiently contribute to the risk of this complex phenotype alone. The joint effects of deleterious variation in these susceptibility loci and Fc receptor genes, which offer fundamental biologically plausible mechanisms for pathological processes, may contribute to our understanding of SLE pathogenesis and natural history of SLE.
Gene-by-environment interactions
Tantamount to the exploitation of gene-gene interactions are evaluations of microenvironment factors that alter Fc receptor expression and function. Several cytokines, chemotactic factors and growth factors have been shown to alter Fcg receptor expression on diverse cell types in an autocrine and paracrine manner. Fcg receptor effector functions may also be altered by reactive oxygen species and serine proteases, which promote differences in receptor phagocytotic and binding capacity, respectively. It is conceivable that additional microenvironmental factors, including infectious agents, sex hormones, C-reactive protein and mannose-binding lectin that correlates with the SLE diathesis, influence Fc receptor function. Such modifying effects may underscore the variation in Fcg receptor gene associations observed with disease and lupus nephritis. This is particularly noteworthy because the pleiotropic effects of these inflammatory molecules act locally to perturb Fcg receptor-mediated IC clearance, leading to chronic inflammation of the glomeruli, fibrinoid necrosis and reduced renal capacity, consistent with lupus nephritis.
Conclusion
The study of Fcg receptors in SLE has a rich heritage dating back over 30 years to the initial Fcg receptormediated clearance studies. Our knowledge of the diversity of Fcg receptor structure and function has developed substantially since that time. On the basis of this increase in knowledge about these receptors, many pivotal mechanistic and genetic studies have reinforced the functional importance of these receptors in the pathogenesis of SLE. As we develop additional tools to assess genomic variants in this region, we will undoubtedly be surprised by the diversity of variation among these genes and gain increased insight into the role of Fcg receptors in SLE.
